LFB

Pre-clinical

Les Ulis, FranceFounded 1994groupe-lfb.com

The LFB Group is a leading French biopharmaceutical laboratory dedicated to providing healthcare professionals with critical medicinal products derived from plasma or recombinant proteins. Operating with a strong public health mission, it serves as an essential link between plasma donors and patients, developing and manufacturing biomedicines for serious, chronic, and rare diseases. With nearly 3,100 employees worldwide and sales of €599.6 million in 2024, LFB is a key player in ensuring therapeutic sovereignty in France while expanding its international footprint across Europe, the Americas, and other global markets.

Founded

1994

Employees

3,000-3,100

Focus

Biologics

AI Company Overview

Technology Platform

Expertise in industrial-scale plasma fractionation to purify therapeutic proteins (immunoglobulins, coagulation factors) and recombinant DNA technology for protein production, supported by contract biomanufacturing (CDMO) capabilities.

Opportunities

Growth opportunities include expanding international sales of its plasma-derived medicines, leveraging its CDMO arm (LFB BIOMANUFACTURING) to serve the growing biotech sector, and capitalizing on European policies favoring healthcare sovereignty to secure its strategic position.

Partnerships for pipeline development, like the one with Arthritis4Cure, offer a path to new therapies.

Risk Factors

Key risks include dependency on the supply and cost of human plasma, intense competition from larger global plasma therapy companies, regulatory and pricing pressures in global healthcare markets, and the inherent complexities and risks of biological manufacturing and quality control.

Competitive Landscape

LFB competes with global giants in plasma-derived therapies like Takeda, CSL Behring, Grifols, and Octapharma. Its differentiation stems from its public health mission and role in French/European healthcare sovereignty, deep expertise in fractionation, and a focus on niche rare diseases. It also faces competition in recombinant factors from companies like Sanofi.